2014, Number 1
Residente 2014; 9 (1)
On anti-lamin B1 autoantibodies as major determinant of thromboprotection in SLE patients displaying antiphospholipid antibodies
Nava A, Rodriguez-Ruiz JA, Orozco-López G, Orozco-Barocio G, Garcia-de la Torre I
PDF size: 243.95 Kb.
ABSTRACTAutoantibodies directed against components of the nuclear lamina have been initially described using the Western-blot technique. IgG autoantibodies against lamin B1 have been properly identified using an enzymatic immunoassay, mainly in systemic lupus erythematosus (SLE) patients’ sera. It is clear from these works that a subgroup of SLE patients display high titers of autoantibodies against lamin B1 (aLB1), and that those aLB1 were not observed in other rheumatic diseases. In addition, these aLB1 were strongly associated with the lupus anticoagulant. A subsequent exciting finding in a group of 259 SLE patients was the frequency of thrombosis displayed depending on aLB1 and lupus anticoagulant (LAC) status as follows: presence of LAC and abscence of aLB1 50%, presence of both LAC and aLB1 22.7%, abscence of both LAC and aLB1 25.5%, abscence of LAC and presence of aLB1 20.8%. This effect associated with the presence of aLB1 was proposed as a «thromboprotection» and was independent of other antiphospholipid-related antibodies tested such as anticardiolipin and anti-beta(2)GPI. The mechanisms involved in this phenomenon remain to be elucidated, although no evidence was found that supports a direct role of lamin B1 in apoptotic blebs.